Royalty Pharma plc Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests
Royalty Pharma plc (RPRX) reported Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests of $1.11 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Shareholders' Equity › Noncontrolling Interest Items
us-gaap:MinorityInterestDecreaseFromRedemptions · last filed 2025-02-12
- Royalty Pharma plc noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2024-12-31 was $0.00.
- Royalty Pharma plc noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2024-09-30 was $0.00.
- Royalty Pharma plc noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2024-06-30 was $0.00.
- Royalty Pharma plc noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2024-03-31 was $1.11M.
- Royalty Pharma plc noncontrolling interest, decrease from redemptions or purchase of interests for fiscal 2024 was $1.11M, a 75.79% decline from fiscal 2023.
- Royalty Pharma plc noncontrolling interest, decrease from redemptions or purchase of interests for fiscal 2023 was $4.58M.
| Period end | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 3 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 6 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 9 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $1.11M 10-K · filed 2025-02-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $1.11M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.11M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $1.11M 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $4.58M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |